after signing the consent form you become part of the study.

the study team records your medical history, performs physical examinations, and collects blood samples and imaging studies to document the status of your advanced lymphoid leukemia.

for paediatric participants a growth curve and puberty assessment are also performed.

the study pharmacy prepares the ucart19 cell product, which is a suspension of allogeneic t cells engineered to express a chimeric antigen receptor that targets cd19.

the product is supplied in one of four concentrations (0.6, 6, 15 or 20 megacells per millilitre). the dose is expressed as cell concentration, not as a weight in milligrams.

the chosen concentration is determined by the study protocol before the infusion day.

on the scheduled day you receive the intravenous infusion of the cell suspension through a vein.

the infusion is administered once, typically over one to two hours, and no additional doses are planned.

during the infusion you are monitored continuously for vital signs and any immediate reactions.

after the infusion you remain in the clinic for several hours to allow the staff to observe any early adverse events.

vital signs, laboratory tests and symptom checklists are recorded before you are discharged.

you attend a follow‑up visit about one week after infusion, then at one month, and subsequently every three months during the first twelve months.

each visit includes physical examination, blood tests, and assessment of any new or ongoing adverse events.

the study may also collect a bone‑marrow sample if it is part of your routine disease monitoring.

after the first year you continue to be evaluated at regular intervals (typically every six months) until the planned end of the study in 2035.

the evaluations focus on the long‑term safety of the cell therapy, recording the number, duration and outcome of any adverse events or events of special interest.

for children, growth and puberty are measured at each visit.

at the conclusion of the study you attend a final visit in which a comprehensive safety assessment is performed.

the final report includes all data collected from the first infusion up to the last follow‑up visit.